Medicamen Biotech Ltd. | Small-cap | Healthcare
₹307.95
2.36%
| Medicamen Biotech Stock Comparison:
Medicamen Biotech vs Sun PharmaceuticalMedicamen Biotech vs Divi's LaboratoriesMedicamen Biotech vs Suven Life SciencesMedicamen Biotech vs Sequent ScientificMedicamen Biotech vs Aarti DrugsMedicamen Biotech vs NIFTY 50 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 430.4M
Gross Profit 203.3M 47.23%
Operating Income 28.1M 6.54%
Net Income 16.0M 3.72%
EPS (Diluted) ₹1.18

Balance Sheet Metrics

Total Assets 3.0B
Total Liabilities 841.0M
Shareholders Equity 2.1B
Debt to Equity 0.39

Cash Flow Metrics

Revenue & Profitability Trend

Medicamen Biotech Income Statement From 2021 to 2025

Metric20252024202320222021
Revenue i1.6B1.8B1.4B1.2B1.1B
Cost of Goods Sold i1.0B926.0M859.9M674.6M792.0M
Gross Profit i605.4M867.1M548.8M479.9M335.2M
Gross Margin % i37.2%48.4%39.0%41.6%29.7%
Operating Expenses
Research & Development i-----
Selling, General & Administrative i132.6M-82.7M77.2M41.5M
Other Operating Expenses i3.3M344.0M3.0M4.6M3.9M
Total Operating Expenses i136.0M344.0M85.7M81.8M45.4M
Operating Income i123.8M151.5M188.9M190.0M171.5M
Operating Margin % i7.6%8.4%13.4%16.5%15.2%
Non-Operating Items
Interest Income i5.1M7.2M7.2M1.4M1.5M
Interest Expense i31.6M44.0M29.2M14.0M10.6M
Other Non-Operating Income-----
Pre-tax Income i98.8M130.8M170.4M180.9M163.9M
Income Tax i33.2M35.8M23.2M32.0M42.6M
Effective Tax Rate % i33.6%27.4%13.6%17.7%26.0%
Net Income i65.6M94.9M147.3M149.0M121.3M
Net Margin % i4.0%5.3%10.5%12.9%10.8%
Key Metrics
EBITDA i201.2M244.9M272.3M259.4M199.7M
EPS (Basic) i₹5.59₹8.63₹11.73₹12.19₹9.93
EPS (Diluted) i₹5.59₹8.63₹11.73₹12.19₹9.93
Basic Shares Outstanding i1271460012659277126511001221660012216600
Diluted Shares Outstanding i1271460012659277126511001221660012216600

Income Statement Trend

Medicamen Biotech Balance Sheet From 2021 to 2025

Metric20252024202320222021
Assets
Current Assets
Cash & Equivalents i37.6M147.9M207.8M38.2M38.9M
Short-term Investments i-----
Accounts Receivable i689.0M552.6M652.6M632.2M525.5M
Inventory i621.4M593.8M450.6M270.1M52.0M
Other Current Assets30.0K256.8M-1.0K237.2M272.5M
Total Current Assets i1.6B1.6B1.6B1.2B960.3M
Non-Current Assets
Property, Plant & Equipment i196.1M192.7M173.3M158.7M140.9M
Goodwill i7.4M9.0M9.0M3.6M2.0M
Intangible Assets i7.4M9.0M9.0M3.6M2.0M
Long-term Investments-----
Other Non-Current Assets414.2M393.7M195.1M88.2M75.6M
Total Non-Current Assets i1.3B1.3B1.2B1.0B976.9M
Total Assets i3.0B2.9B2.8B2.3B1.9B
Liabilities
Current Liabilities
Accounts Payable i426.5M367.0M431.7M433.0M322.1M
Short-term Debt i300.4M298.6M248.4M207.2M124.1M
Current Portion of Long-term Debt-----
Other Current Liabilities957.0K81.5M39.8M20.3M400.0K
Total Current Liabilities i781.6M845.6M825.7M726.9M532.7M
Non-Current Liabilities
Long-term Debt i37.3M12.6M8.7M50.7M64.0M
Deferred Tax Liabilities i-30.0K0000
Other Non-Current Liabilities6.0K-1.0K-1.0K1.0K
Total Non-Current Liabilities i59.4M30.1M25.3M65.3M75.6M
Total Liabilities i841.0M875.7M851.0M792.2M608.3M
Equity
Common Stock i127.1M127.1M126.5M122.2M122.2M
Retained Earnings i963.1M907.7M825.4M687.8M551.1M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i2.1B2.1B1.9B1.5B1.3B
Key Metrics
Total Debt i337.7M311.1M257.1M258.0M188.2M
Working Capital i863.9M750.4M807.9M503.5M427.6M

Balance Sheet Composition

Medicamen Biotech Cash Flow Statement From 2021 to 2025

Metric20252024202320222021
Operating Activities
Net Income i65.6M94.9M147.3M149.0M121.3M
Depreciation & Amortization i-----
Stock-Based Compensation i-----
Working Capital Changes i-263.0M-153.6M-288.7M-250.9M25.1M
Operating Cash Flow i-170.9M-21.9M-119.4M-89.3M155.5M
Investing Activities
Capital Expenditures i-21.9M-62.9M-66.0M-86.1M-179.7M
Acquisitions i-----
Investment Purchases i00000
Investment Sales i-----
Investing Cash Flow i-19.0M-62.9M-66.0M-86.1M-179.7M
Financing Activities
Share Repurchases i-----
Dividends Paid i-12.7M-12.7M-12.7M-12.2M-6.1M
Debt Issuance i16.7M3.9M--40.5M
Debt Repayment i-430.0K--42.0M-13.3M-
Financing Cash Flow i8.3M107.1M324.6M57.0M69.0M
Free Cash Flow i-103.5M-130.3M-128.9M-45.0M-51.9M
Net Change in Cash i-181.7M22.3M139.3M-118.4M44.9M

Cash Flow Trend

Medicamen Biotech Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 48.18
Price to Book 1.76
Price to Sales 2.47
PEG Ratio 4.37

Profitability Ratios

Profit Margin 4.87%
Operating Margin 6.54%
Return on Equity 3.34%
Return on Assets 2.39%

Financial Health

Current Ratio 2.11
Debt to Equity 15.63
Beta 0.64

Per Share Data

EPS (TTM) ₹6.13
Book Value per Share ₹167.35
Revenue per Share ₹136.43

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
medicameq4.0B48.181.763.34%4.87%15.63
Sun Pharmaceutical 3.9T36.745.3015.08%19.29%3.26
Divi's Laboratories 1.6T65.3710.1314.64%23.89%0.03
Suven Life Sciences 48.2B-28.0140.49-146.15%84.44%0.00
Sequent Scientific 48.1B166.336.612.84%1.85%62.47
Aarti Drugs 44.5B23.663.2612.28%7.80%44.92

Financial data is updated regularly. All figures are in the company's reporting currency.